

PLAG1 Antibody (monoclonal) (M02)

Mouse monoclonal antibody raised against a partial recombinant PLAG1. Catalog # AT3333a

Product Information

Application	WB, E
Primary Accession	<u>Q6DJT9</u>
Other Accession	<u>NM_002655</u>
Reactivity	Human
Host	mouse
Clonality	monoclonal
Isotype	IgG2a Kappa
Clone Names	3B7
Calculated MW	55909

Additional Information

Gene ID	5324
Other Names	Zinc finger protein PLAG1, Pleiomorphic adenoma gene 1 protein, PLAG1
Target/Specificity	PLAG1 (NP_002646, 2 a.a. ~ 99 a.a) partial recombinant protein with GST tag. MW of the GST tag alone is 26 KDa.
Dilution	WB~~1:500~1000 E~~N/A
Format	Clear, colorless solution in phosphate buffered saline, pH 7.2 .
Storage	Store at -20°C or lower. Aliquot to avoid repeated freezing and thawing.
Precautions	PLAG1 Antibody (monoclonal) (M02) is for research use only and not for use in diagnostic or therapeutic procedures.

Background

Pleomorphic adenoma gene 1 encodes a zinc finger protein with 2 putative nuclear localization signals. PLAG1, which is developmentally regulated, has been shown to be consistently rearranged in pleomorphic adenomas of the salivary glands. PLAG1 is activated by the reciprocal chromosomal translocations involving 8q12 in a subset of salivary gland pleomorphic adenomas. Three transcript variants encoding two different isoforms have been found for this gene.

References

1.miRNA deregulation by epigenetic silencing disrupts suppression of the oncogene PLAG1 in chronic lymphocytic leukemia.Pallasch CP, Patz M, Park YJ, Hagist S, Eggle D, Claus R, Debey-Pascher S, Schulz A,

Frenzel LP, Claasen J, Kutsch N, Krause G, Mayr C, Rosenwald A, Plass C, Schultze JL, Hallek M, Wendtner CM.Blood. 2009 Oct 8;114(15):3255-64. Epub 2009 Aug 19.



Images

Antibody Reactive Against Recombinant Protein.Western Blot detection against Immunogen (36.52 KDa) .

Detection limit for recombinant GST tagged PLAG1 is approximately 0.03ng/ml as a capture antibody.

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.